Holly Lumgair

With a neuroscience degree and research experience gained in Austria, Holly’s background started within life sciences communications before choosing to move into Early Access. Holly has now worked in the field of Early Access for over 10 years, having had direct or indirect exposure to many key Early Access Programs across oncology and rare disease over the past decade. Over the past 7 years, Holly has developed a passion for engaging and empowering patient groups about Early Access, driving awareness, and supporting patients with unmet medical needs across geographies and disease areas. More recently, Holly has worked to pioneer and act as secretariat for the Bioethics Advisory (Beta) Group. This independent group exists to assist industry in bringing multidisciplinary ethics to bear on their Early Access decision-making, and to contribute to the dialogue on Early Access and its place in society. As Patient Advocacy Lead for Clinigen Group, Holly also directs Patient Advocacy across the Group’s portfolio of medicines, and creates initiatives internally to engage employees in fostering an ongoing patient-focused business.